Results from first global survey of neuroendocrine tumor (NET) patients reveal profound impact of this rare cancer on quality of life
The International Neuroendocrine Cancer Alliance (INCA) and Novartis announced the quality-of-life results from the first global survey of patients with neuroendocrine tumors (NETs), a rare type of cancer. Nearly 2,000 patients from 12 countries completed the survey, which was a collaborative effort between INCA and Novartis. The results were presented at a medical meeting and provide compelling data documenting the impact of NETs on people living with this disease. These quality-of-life findings are the first in a series of results from the survey being released in conjunction with Worldwide NET Cancer Awareness Day (WNCAD), November 10. Read the full results at NET Cancer Day.